Zevra Therapeutics ZVRA
NASDAQ ZVRA
$10.44 -0.03 (-0.33%)
As of: Oct 21, 2026 · 3:25 PM EDT

Zevra Therapeutics (ZVRA) Cash from Restructuring (2023)

Updated

Analysis

Zevra Therapeutics (ZVRA) Cash from Restructuring (2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.85 Bn 1,106.43 Bn 19.71 Bn
2 Johnson & Johnson 618.85 Bn 537.37 Bn 17.26 Bn
3 AbbVie 503.03 Bn 476.14 Bn 12.70 Bn
4 Merck 368.52 Bn 322.90 Bn 12.21 Bn
5 Novartis Ag 298.19 Bn 262.18 Bn 11.24 Bn
6 Astrazeneca 261.33 Bn 235.02 Bn 12.86 Bn
7 Amgen 237.14 Bn 192.53 Bn 7.24 Bn
8 Gilead Sciences 191.35 Bn 165.54 Bn 6.22 Bn
9 Pfizer 169.80 Bn 116.45 Bn 10.94 Bn
10 Zevra Therapeutics 617.29 Mn -195.41 Mn 38.18 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2023 354,000.00
API Access

Zevra Therapeutics Cash from Restructuring API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-restructuring&ticker=ZVRA&period=max&api_key=YOUR_API_KEY